QPS Holdings LLC and Hepregen Announce HepatoPac Commercial Partnership
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEWARK, Del. & MEDFORD, Mass.--(BUSINESS WIRE)--QPS Holdings, LLC, a US-headquartered contract research organization (“CRO”), and Hepregen Corporation, developer of HepatoPacTM and HepatoMuneTM “liver-in-a-dish” products, announced today the execution of an agreement between the companies that provides QPS a license to offer drug metabolism and pharmacokinetic (“DMPK”) services to its clients using Hepregen’s unique, paradigm-shifting products. The agreement provides for offerings in both North America and Europe. The agreement also creates a marketing and sales partnership between the companies, providing for co-promotion of the HepatoPacTM-associated DMPK services. This arrangement is the first such partnership in the field for both companies.
Help employers find you! Check out all the jobs and post your resume.
NEWARK, Del. & MEDFORD, Mass.--(BUSINESS WIRE)--QPS Holdings, LLC, a US-headquartered contract research organization (“CRO”), and Hepregen Corporation, developer of HepatoPacTM and HepatoMuneTM “liver-in-a-dish” products, announced today the execution of an agreement between the companies that provides QPS a license to offer drug metabolism and pharmacokinetic (“DMPK”) services to its clients using Hepregen’s unique, paradigm-shifting products. The agreement provides for offerings in both North America and Europe. The agreement also creates a marketing and sales partnership between the companies, providing for co-promotion of the HepatoPacTM-associated DMPK services. This arrangement is the first such partnership in the field for both companies.
Help employers find you! Check out all the jobs and post your resume.